IN8bio Statistics

Total Valuation

IN8bio has a market cap or net worth of $18.03 million. The enterprise value is $19.50 million.

Market Cap	18.03M
Enterprise Value	19.50M

Important Dates

The last earnings date was Tuesday, November 12, 2024, after market close.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

IN8bio has 72.48 million shares outstanding. The number of shares has increased by 56.99% in one year.

Current Share Class	72.48M
Shares Outstanding	72.48M
Shares Change (YoY)	+56.99%
Shares Change (QoQ)	+4.86%
Owned by Insiders (%)	11.27%
Owned by Institutions (%)	18.23%
Float	54.25M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.36
P/TBV Ratio	2.10
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.84, with a Debt / Equity ratio of 0.64.

Current Ratio	1.84
Quick Ratio	1.10
Debt / Equity	0.64
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -241.97% and return on invested capital (ROIC) is -105.53%.

Return on Equity (ROE)	-241.97%
Return on Assets (ROA)	-92.78%
Return on Capital (ROIC)	-105.53%
Revenue Per Employee	n/a
Profits Per Employee	-$1.03M
Employee Count	31
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.84% in the last 52 weeks. The beta is 0.00, so IN8bio's price volatility has been lower than the market average.

Beta (5Y)	0.00
52-Week Price Change	-82.84%
50-Day Moving Average	0.30
200-Day Moving Average	0.71
Relative Strength Index (RSI)	39.26
Average Volume (20 Days)	748,944

Short Selling Information

The latest short interest is 859,263, so 1.19% of the outstanding shares have been sold short.

Short Interest	859,263
Short Previous Month	1.34M
Short % of Shares Out	1.19%
Short % of Float	1.58%
Short Ratio (days to cover)	0.51

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-31.30M
Pretax Income	-31.96M
Net Income	-31.88M
EBITDA	-29.50M
EBIT	-31.30M
Earnings Per Share (EPS)	-$0.74

Full Income Statement

Balance Sheet

The company has $4.00 million in cash and $5.47 million in debt, giving a net cash position of -$1.47 million or -$0.02 per share.

Cash & Cash Equivalents	4.00M
Total Debt	5.47M
Net Cash	-1.47M
Net Cash Per Share	-$0.02
Equity (Book Value)	8.59M
Book Value Per Share	0.18
Working Capital	3.07M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$24.97 million and capital expenditures -$226,000, giving a free cash flow of -$25.20 million.

Operating Cash Flow	-24.97M
Capital Expenditures	-226,000
Free Cash Flow	-25.20M
FCF Per Share	-$0.35

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

IN8bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-56.99%
Shareholder Yield	-56.99%
Earnings Yield	-176.75%
FCF Yield	-139.72%

Analyst Forecast

The average price target for IN8bio is $7.75, which is 3,014.95% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.75
Price Target Difference	3,014.95%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1